Effects of Prazosin and Other Alpha-1 Adrenergic Antagonist Drugs on Nightmares and Sleep Disturbances in Posttraumatic Stress Disorder

Chronic insomnia, common in PTSD, leads to depression, cognitive impairment, and substance abuse. Sleep abnormalities in PTSD include trauma-related nightmares, prolonged sleep latency, frequent interruptions, and disrupted sleep cycles. This review examines pharmacological treatment for nightmares, focusing on noradrenergic signaling and alpha-1 adrenergic blocking agents like prazosin. Randomized controlled trials suggest prazosin's clinical efficacy for PTSD-related nightmare disorder in subpopulations. Case studies, pilot, and open-label trials indicate possible clinical use of terazosin, tamsulosin, and doxazosin, but further RCTs are needed. Prazosin has the best evidence base; when not feasible, alternative alpha-1 blockers may be effective in a subset of patients.

Study at a glance

Abstract

PURPOSE/BACKGROUND: Chronic insomnia causes malaise and is associated with depression, irritability, cognitive impairment, impaired alertness, and substance abuse. Individuals with posttraumatic stress disorder (PTSD) often have both inadequate and fragmented sleep, putting them at elevated risk for these consequences. Sleep abnormalities in patients with PTSD include frequent trauma-related nightmares, prolonged sleep latency, frequent interruptions, early awakening, nighttime behavioral disorders, and disruptions of sleep cycles. Here, we review the pharmacological treatment for nightmares with an emphasis on noradrenergic (NA) signaling, following the clinical observation that medication treatment with alpha-1 adrenergic blocking agents, such as prazosin, improves nightmares. METHODS/PROCEDURES: We discuss the randomized controlled trials (RCTs) examining prazosin's impact on nightmares, including its efficacy and safety, and the limitations of the studies. In addition, we review the accumulating evidence from case reports, chart review, and small studies for several other anti-alpha-1 agents (specifically doxazosin, terazosin, and tamsulosin) and their efficacy in treating nightmares in PTSD. FINDINGS/RESULTS: RCT studies for prazosin suggest clinical efficacy for PTSD-related nightmare disorder in subpopulations of individuals with this condition. Case studies, pilot, and open label trails suggest possible clinical use of terazosin, tamsulosin, and doxazosin in PTSD-related nightmares, however, further RCTs are needed. IMPLICATIONS/CONCLUSIONS: When available and clinically tolerated, prazosin continues to have the best evidence base for use in PTSD-related nightmares. When prazosin use is not feasible, alternative alpha-1 blockers may be effective in a subset of patients.